Lanean...
Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1
PURPOSE OF REVIEW: Immune checkpoint blockade (ICB) has changed the clinical course of multiple cancer types and durable responses have now been observed in breast cancer (BC) patients. Most data suggest that, compared to other subtypes, triple-negative BC (TNBC) patients are more responsive to ICB,...
Gorde:
| Argitaratua izan da: | Curr Breast Cancer Rep |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7731906/ https://ncbi.nlm.nih.gov/pubmed/33312343 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12609-019-00331-5 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|